|
WO2021076771A1
|
|
Curcuminoid composition and its therapeutic potential in managing lung fibrosis
|
|
WO2021041559A1
|
|
Plant actives and their anti-pollution effects thereof
|
|
US2020316143A1
|
|
Compositions and methods for management of atrophic gastritis and colitis
|
|
US2020316140A1
|
|
Method and composition for therapeutic management of gluten intolerance
|
|
US2020188350A1
|
|
Bioactive molecules from oroxylum indicum and their therapeutic applications
|
|
WO2020168141A1
|
|
Method of isolating secondary metabolites from cambium derived callus cultures
|
|
US2020276257A1
|
|
Composition for therapeutic management of hypomelanotic skin conditions
|
|
WO2020146635A1
|
|
Water-soluble mineral ferulates and their method of preparation
|
|
US2020030388A1
|
|
Compositions for modifying gut microbiota
|
|
US2021093582A1
|
|
Compositions for reducing trimethylamine-n-oxide and related therapeutic applications
|
|
US2020024296A1
|
|
Process for the isolation of novel glycosides from pterocarpus marsupium and their therapeutic effects
|
|
US2019381000A1
|
|
Bioactive molecules from oroxylum indicum and their therapeutic applications
|
|
WO2020246976A1
|
|
Composition for prostaglandin transporter inhibition and related therapeutic applications
|
|
US2020384059A1
|
|
Composition for prostaglandin transporter inhibition and related therapeutic applications
|
|
WO2020231397A1
|
|
Fructophilic lactic acid producing bacteria
|
|
US2020360448A1
|
|
Fructophilic lactic acid producing bacteria
|
|
WO2019212929A1
|
|
Compositions for weight loss
|
|
US2020268822A1
|
|
Aphrodisiac composition and management of male sexual dysfunction
|
|
US2020316139A1
|
|
Stable probiotic composition for the management of lactose intolerance
|
|
WO2020204910A1
|
|
Stable probiotic composition for the management of lactose intolerance
|
